Trial Profile
Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC).
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 04 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Mar 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.